Espironolactona en la coriorretinopatía central serosa

espanolCaso clinico: Varon de 43 anos de edad sin antecedentes personales de interes, remitido para cirugia de hidrocistoma ecrino en parpado inferior de ojo izquierdo. A la semana de la misma refiere disminucion de agudeza visual ipsilateral, visualizandose coriorretinopatia central serosa, sin mejoria espontanea y persistente en el tiempo durante ocho meses, hasta la instauracion de 50 mg de espironolactona diarias, observandose resolucion del cuadro retiniano. Discusion: Existe evidencia de que la espironolactona es capaz de antagonizar los receptores de la aldosterona de la retina. Se demuestra la eficacia y se dilucida prometedor en el tratamiento de esta patologia retiniana. EnglishCase report: 43-year-old male with no relevant medical history, referred for eccrine hydrocystoma surgery in lower eyelid, left eye. A week after, he shows a decreased visual acuity as well as a central serous chorioretinopathy that did not improve spontaneously and persisted over time for eight months until the treatment with spironolactone, 50 mg daily, was prescribed and the retinal disease eventually resolved. Discussion: There is evidence that spironolactone is able to antagonise the aldosterone receptors in the retina. Its efficacy has been proved and can be foreseen as a promising drug in the treatment of this retinal disease.